The market for therapeutics to fight Crohn's disease and irritable bowel syndrome will continue to grow from 2010-2017, due to a panoply of new drugs hitting the market, according to a Reportlinker news release.
However, the market for gastrointestinal disorder therapeutics will decline in that period, due to negative growth of the gastroesophageal reflux disease therapeutics as patents lapse and more drugs become generic.
Patent expirations of major drugs have increased competition, driving further consolidation and more use of licensing agreements.
Related Articles on Gastrointestinal Drugs:
10 Recent Studies and Breakthroughs Impacting Gastroenterology/Endoscopy
PPI Use in GI Treatment May Increase Risk of Fractures, Infections
Experimental Colon Cancer Drug Shows Effectiveness in Trial